Efficacy and safety of single-agent ibrutinib in rituximab-refractory patients with Waldenström’s macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATETM): 195

Scientific publication - Journal Article uoadl:2951152 20 Read counter

Description
Contents

Unit:

Faculty of Medicine

Title:

Efficacy and safety of single-agent ibrutinib in rituximab-refractory patients with Waldenström’s macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATETM): 195

Languages of Item:

English

Abstract:

Empty abstract

Publication year:

2016

Authors:

Dimopoulos, M
Trotman, J
Tedeschi, A
Matous, J
Macdonald, D
Tam, C
Tournilhac, O
Ma, S
Oriol, A
Heffner, L
others

Journal:

British Journal of Haematology

Volume:

173

Main subject category:

Health Sciences

Persistent URL:

https://pergamos.lib.uoa.gr/uoa/dl/object/2951152

Efficacy and safety of single-agent ibrutinib in rituximab-refractory patients with Waldenström’s macroglobulinemia (WM): Initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATETM): 195

The digital material of the item is not available.